Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
Applied DNA’s CEO and Chairman of the Board of Directors, Dr. James A. Hayward, will present in person and provide an overview of the Company’s business during the presentation.
To listen to a livestream of the Company’s presentation, please click on the following link to register for the conference: Applied DNA presentation at the H.C. Wainwright 24th Annual Global Investment Conference
Event: H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
Date: September 13, 2022
Time: 2:00 pm Eastern Time
Location: In-person at the Lotte New York Palace Hotel, New York, NY.
Note: To schedule a one-on-one with management, please get in touch with your H.C. Wainwright representative.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using PCR to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
The Company’s common stock is listed on NASDAQ under the ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under the ticker symbol ‘APPDW.’